arrow
C

Chris Pepper

department of clinical and experimental medicine
H指数:50
被引数:6,966
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.

TLR9依赖性迁移识别BTK抑制下慢性淋巴细胞白血病的不同信号状态。

Blood
IF23.1
2026-10-070
PRE
Exploring the Bone Marrow Microenvironment as a Therapeutic Barrier and Targetable Source of Crosstalk in Acute Myeloid Leukemia

探索骨髓微环境作为急性髓系白血病中的治疗屏障和可靶向的串扰来源

2026-05-190
OAAI
Design, Synthesis, and Biological Evaluation of Efflux-Resistant Imatinib Derivatives
2025-10-010
PRE
Systems biology-enabled targeting of NF-κΒ and BCL2 overcomes microenvironment-mediated BH3-mimetic resistance in DLBCL

系统生物学赋能的NF-κΒ和BCL2靶向克服了DLBCL中微环境介导的BH3-模拟剂耐药性

2025-08-160
OAAI
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data
2024-07-040
OAAI
A therapeutic antibody targeting annexin-A1 inhibits cancer cell growth in vitro and in vivo
2024-01-105
OAAI
Computational modeling of DLBCL predicts response to BH3-mimetics
2023-06-064
OAAI
NF-κB fingerprinting reveals heterogeneous NF-κB composition in diffuse large B-cell lymphoma
2023-06-021
OAAI
NF-kB and the CLL microenvironment
2023-03-3017
OAAI
Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3′-Deoxyadenosine, as a Potential Anticancer Agent
2022-11-2310
OAAI
DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies
2022-07-292
OAAI
MDX-124, a novel annexin-A1 antibody, shows anti-tumor efficacy in several preclinical models of triple-negative breast cancer
2022-02-150
PRE
TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia
2021-07-2032
OA
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
LEUKEMIA
IF13.4
2021-06-194
OAAI
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro
2021-06-0413
OAAI
Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents
2021-03-0116
OAAI
Transcriptomics-Based Characterization of the Toxicity of ZnO Nanoparticles Against Chronic Myeloid Leukemia Cells
2020-10-0123
OAAI
Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit nuclear factor-KB activity and synergize with bortezomib and ibrutinib in hematologic cancers
2020-05-076
OAAI
Clinical utility of telomere length measurements in cancer
2020-02-014
OAAI
Targeting CDK9 for treatment of colorectal cancer
2019-08-2140
OAAI